Chamazulene

Chamazulene at a Glance

Chamazulene is the pigment responsible for the striking deep-blue colour of German chamomile and yarrow essential oils. Chemically it is an aromatic sesquiterpene of the azulene family — the same fused five-/seven-membered ring system that gives all azulenes their unusual blue-violet colour.

Its single most important feature is that it is not really a plant compound at all: it is a distillation artifact. The fresh flower contains almost no chamazulene. What it contains is a colourless precursor, matricin, which breaks down under the heat of steam distillation to form the blue azulene ^{1Reference 1Gabbanini S et al. · 2024Photochemical and oxidative degradation of chamazulene contained in Artemisia, Matricaria and Achillea essential oils and setup of protection strategiesView study →}. This is why chamomile essential oil is inky blue while a cup of chamomile tea is pale gold — the tea never reaches the temperature that makes the blue.

Chamazulene carries much of the traditional anti-inflammatory reputation of chamomile- and yarrow-oil preparations. In the laboratory the isolated molecule is a genuine antioxidant and inhibitor of leukotriene-B4 formation ^{2,3Reference 2Safayhi H et al. · 1994Chamazulene: an antioxidant-type inhibitor of leukotriene B4 formationView study →Reference 3Rekka EA et al. · 1996Investigation of the effect of chamazulene on lipid peroxidation and free radical processesView study →}, but that evidence is entirely in-vitro; the clinical use of chamomile and yarrow is of the whole extract, not of purified chamazulene ^{9Reference 9Srivastava JK et al. · 2010Chamomile: a herbal medicine of the past with a bright futureView study →}.

The Blue That Isn’t in the Plant

The defining fact about chamazulene is chemical timing: it forms during processing, not in the growing plant. German chamomile, yarrow and several Artemisia species store a family of colourless sesquiterpene lactones called proazulenes — chiefly matricin in chamomile and its close relative achillicin in yarrow. On steam distillation, the heat drives matricin through an intermediate, chamazulene carboxylic acid, and on to chamazulene itself, which is what turns the collected oil blue ^{1,6Reference 1Gabbanini S et al. · 2024Photochemical and oxidative degradation of chamazulene contained in Artemisia, Matricaria and Achillea essential oils and setup of protection strategiesView study →Reference 6Ramadan M et al. · 2006Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substancesView study →}.

That single mechanism explains several things at once:

Why the oil is blue but the tea and tincture are not. A water infusion or a cold alcoholic tincture never subjects matricin to distillation heat, so little chamazulene forms and the preparation stays pale. The blue is a signature of the essential oil, produced by the method.
Why chamazulene content is so variable. Reported levels swing from a trace to around 44% of the essential oil depending on the plant’s chemotype (azulene-rich vs. azulene-free lines, often tied to ploidy), the plant part, and how the oil was distilled ^{7Reference 7Németh E · 2008Biological activities of yarrow species (Achillea spp.)View study →}. Yarrow in particular splits into azulene-rich and azulene-free chemotypes, and commercial quality is uneven — in one survey only about half of 40 commercial yarrow samples met European Pharmacopoeia standards for essential-oil and proazulene content ^{8Reference 8Benedek B et al. · 2008Yarrow (Achillea millefolium L. s.l.): pharmaceutical quality of commercial samplesView study →}.
Why the blue fades. Chamazulene is volatile and unstable to light and air. Under UV exposure it photo-oxidises through a series of degradation products, and the oil visibly shifts blue → green → yellow as the chromophore is destroyed; degradation is markedly faster in the presence of oxygen and in polar solvents, and is largely suppressed under nitrogen or with an added antioxidant such as α-tocopherol ^{1Reference 1Gabbanini S et al. · 2024Photochemical and oxidative degradation of chamazulene contained in Artemisia, Matricaria and Achillea essential oils and setup of protection strategiesView study →}. A blue oil that has gone green or brown has, quite literally, lost its chamazulene.

One honest caveat runs through this section: the closely related chamazulene carboxylic acid (the intermediate, not the final hydrocarbon) is the species with the best human pharmacokinetic data — when volunteers took matricin orally, it was chamazulene carboxylic acid, not chamazulene, that appeared in plasma in the micromolar range, formed in the acidic stomach ^{6Reference 6Ramadan M et al. · 2006Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substancesView study →}. Chamazulene proper is the decarboxylated, oil-soluble end product; the two are relatives, and evidence for one should not be silently transferred to the other.

Anti-Inflammatory Research

Chamazulene’s laboratory reputation rests on two overlapping activities — it is an antioxidant, and it is an inhibitor of leukotriene-B4 formation — and these together are the plausible mechanism behind the anti-inflammatory reputation of chamomile and yarrow oil.

The key isolate study found that chamazulene inhibits the formation of leukotriene B4 — a potent pro-inflammatory lipid mediator made by 5-lipoxygenase — in intact cells and in cell-free preparations, with IC50 values around 10–15 µM, and separately blocks the chemical peroxidation of arachidonic acid at about 2 µM. Notably, chamazulene did this but its precursor matricin did not, and the authors concluded that chamazulene, not matricin, may be what contributes to chamomile’s anti-inflammatory activity, working through both leukotriene inhibition and a general antioxidant effect ^{2Reference 2Safayhi H et al. · 1994Chamazulene: an antioxidant-type inhibitor of leukotriene B4 formationView study →}.

That antioxidant character is well replicated. Chamazulene inhibits lipid peroxidation (IC50 ~18 µM) and scavenges hydroxyl radicals in a concentration- and time-dependent way ^{3Reference 3Rekka EA et al. · 1996Investigation of the effect of chamazulene on lipid peroxidation and free radical processesView study →}; in radical-scavenging assays it is a stronger antioxidant than α-tocopherol or BHT on a concentration basis ^{4Reference 4Capuzzo A et al. · 2014Antioxidant and radical scavenging activities of chamazuleneView study →}; and in cultured endothelial cells it lowered intracellular reactive-oxygen-species levels driven by high glucose and hydrogen peroxide ^{5Reference 5Querio G et al. · 2018Chamazulene attenuates ROS levels in bovine aortic endothelial cells exposed to high glucose concentrations and hydrogen peroxideView study →}. Reviews of yarrow place chamazulene among the compounds behind the oil’s documented antioxidant and anti-inflammatory effects ^{7Reference 7Németh E · 2008Biological activities of yarrow species (Achillea spp.)View study →}.

The load-bearing honesty here: all of this is in-vitro isolate data. It gives a coherent, believable mechanism for why the blue oil soothes inflammation, but it is not the same as a clinical trial of chamazulene in people. The human evidence base belongs to whole chamomile and yarrow preparations ^{9Reference 9Srivastava JK et al. · 2010Chamomile: a herbal medicine of the past with a bright futureView study →}, within which chamazulene is one active among many (alongside α-bisabolol, apigenin and other flavonoids and sesquiterpene lactones).

What It's Used For

Chamazulene’s pharmacology is real but narrow and preclinical: an antioxidant azulene that also damps one branch of the eicosanoid cascade. The evidence is in-vitro on the isolated molecule; there are no controlled human trials of chamazulene itself.

Leukotriene-B4 inhibition with an antioxidant signature:chamazulene inhibits LTB4 formation (IC50 ~10–15 µM) and blocks arachidonic-acid peroxidation (IC50 ~2 µM); its precursor matricin does not, implicating chamazulene as the anti-inflammatory principle of the oil ^{2Reference 2Safayhi H et al. · 1994Chamazulene: an antioxidant-type inhibitor of leukotriene B4 formationView study →}.

A robust in-vitro antioxidant:it inhibits lipid peroxidation, scavenges hydroxyl and ABTS radicals more strongly than α-tocopherol/BHT in assay, and lowers endothelial ROS ^{3,4,5Reference 3Rekka EA et al. · 1996Investigation of the effect of chamazulene on lipid peroxidation and free radical processesView study →Reference 4Capuzzo A et al. · 2014Antioxidant and radical scavenging activities of chamazuleneView study →Reference 5Querio G et al. · 2018Chamazulene attenuates ROS levels in bovine aortic endothelial cells exposed to high glucose concentrations and hydrogen peroxideView study →}.

The honest headline:every one of these is isolate in-vitro work. Chamomile’s and yarrow’s actual clinical use is the whole extract ^{9Reference 9Srivastava JK et al. · 2010Chamomile: a herbal medicine of the past with a bright futureView study →}, and the best human pharmacokinetic data are for the sibling chamazulene carboxylic acid, not chamazulene ^{6Reference 6Ramadan M et al. · 2006Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substancesView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here is isolated-molecule in-vitro work, so scores stay modest by design.

Mechanisms

Target / pathway	Effect	Relevant to
5-Lipoxygenase / leukotriene B4	inhibits LTB4 formation (IC50 ~10–15 µM)	anti-inflammatory
Arachidonic-acid peroxidation	blocks chemical peroxidation (IC50 ~2 µM) — antioxidant-type action	anti-inflammatory / antioxidant
Lipid peroxidation / hydroxyl radicals	inhibits lipid peroxidation (IC50 ~18 µM); scavenges hydroxyl radicals	antioxidant
ABTS / DPPH radicals	strong radical scavenging, exceeding α-tocopherol and BHT in vitro	antioxidant
Intracellular ROS (high glucose / H2O2)	lowers ROS in endothelial cells	antioxidant / vascular
Cyclo-oxygenase-2 (via chamazulene carboxylic acid)	the carboxylic-acid relative inhibits COX-2 but not COX-1 — a natural “profen”; chamazulene is its decarboxylated end product	anti-inflammatory (related molecule)

The load-bearing point: chamazulene’s anti-inflammatory action is best read as antioxidant leukotriene inhibition rather than classical COX blockade — the COX-2 activity belongs to the carboxylic-acid intermediate, not to the blue hydrocarbon itself ^{2,6Reference 2Safayhi H et al. · 1994Chamazulene: an antioxidant-type inhibitor of leukotriene B4 formationView study →Reference 6Ramadan M et al. · 2006Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substancesView study →}.

Pharmacokinetics

There is no established human pharmacokinetic profile for isolated chamazulene. It is a small, lipophilic, volatile hydrocarbon, so it distributes readily into oils and lipids, but it is also chemically unstable to light and oxygen, photo-oxidising through coloured degradation products — a property that undercuts any assumption of stable systemic exposure ^{1Reference 1Gabbanini S et al. · 2024Photochemical and oxidative degradation of chamazulene contained in Artemisia, Matricaria and Achillea essential oils and setup of protection strategiesView study →}. The one relevant human dataset concerns the precursor–intermediate pair: when volunteers took matricin orally, it was converted in the acidic stomach to chamazulene carboxylic acid, which reached micromolar plasma levels — but this is the carboxylic acid, not chamazulene, and matricin was not converted in simulated intestinal fluid ^{6Reference 6Ramadan M et al. · 2006Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substancesView study →}. Absorption, bioavailability and half-life of chamazulene proper in humans are uncharacterised.

Clinical Trials

There are no controlled clinical trials of isolated chamazulene. Human evidence sits at the level of whole chamomile and yarrow preparations, where chamazulene is one constituent among many ^{9Reference 9Srivastava JK et al. · 2010Chamomile: a herbal medicine of the past with a bright futureView study →}; the isolate literature is entirely in-vitro/mechanistic.

Completed	Planned	Terminated	Preclinical
None for the isolate (whole chamomile/yarrow extracts studied clinically)	—	—	Leukotriene-inhibition + antioxidant mechanistic (in vitro)

Last checked: July 2026.

Isolate vs. Plant Studies

Chamazulene sits firmly on the isolate-mechanism, whole-plant-clinical side of the line. The mechanistic work — leukotriene-B4 inhibition ^{2Reference 2Safayhi H et al. · 1994Chamazulene: an antioxidant-type inhibitor of leukotriene B4 formationView study →}, lipid-peroxidation and radical scavenging ^{3,4Reference 3Rekka EA et al. · 1996Investigation of the effect of chamazulene on lipid peroxidation and free radical processesView study →Reference 4Capuzzo A et al. · 2014Antioxidant and radical scavenging activities of chamazuleneView study →}, endothelial ROS reduction ^{5Reference 5Querio G et al. · 2018Chamazulene attenuates ROS levels in bovine aortic endothelial cells exposed to high glucose concentrations and hydrogen peroxideView study →} — was all done on the purified molecule in vitro, and as a mechanism base for the isolate that is a genuine strength. But the human/clinical use is the whole oil or extract: chamomile and yarrow are used and studied as complex botanical preparations ^{9Reference 9Srivastava JK et al. · 2010Chamomile: a herbal medicine of the past with a bright futureView study →}, and even the best oral human data belong to a different (if related) molecule, chamazulene carboxylic acid, generated from matricin in the gut ^{6Reference 6Ramadan M et al. · 2006Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substancesView study →}. Two further wrinkles make direct extrapolation risky: chamazulene’s share of the oil swings from trace to ~44% with chemotype and distillation ^{7Reference 7Németh E · 2008Biological activities of yarrow species (Achillea spp.)View study →}, and its instability to air and light means a given batch of “blue oil” may contain far less active chamazulene than its colour once implied ^{1,8Reference 1Gabbanini S et al. · 2024Photochemical and oxidative degradation of chamazulene contained in Artemisia, Matricaria and Achillea essential oils and setup of protection strategiesView study →Reference 8Benedek B et al. · 2008Yarrow (Achillea millefolium L. s.l.): pharmaceutical quality of commercial samplesView study →}.

Prevalence in Nature

Strictly speaking, chamazulene has no natural abundance in the living plant — it is generated during processing. What the plant actually stores are the colourless proazulenes (matricin in German chamomile, achillicin and related guaianolides in yarrow), which are converted to chamazulene under distillation heat ^{1,7Reference 1Gabbanini S et al. · 2024Photochemical and oxidative degradation of chamazulene contained in Artemisia, Matricaria and Achillea essential oils and setup of protection strategiesView study →Reference 7Németh E · 2008Biological activities of yarrow species (Achillea spp.)View study →}. The molecule therefore “occurs” in steam-distilled essential oils rather than in fresh tissue, tea or cold tincture.

Among those oils it is most associated with:

German chamomile (Matricaria chamomilla) — the archetypal blue oil.
Yarrow (Achillea millefolium) — azulene-rich chemotypes yield a blue oil; content runs from a trace up to about 44% of the essential oil, while azulene-free chemotypes yield little or none ^{7Reference 7Németh E · 2008Biological activities of yarrow species (Achillea spp.)View study →}.
Wormwood (Artemisia absinthium) and mugwort (Artemisia vulgaris) — several Artemisia species yield chamazulene-containing oils.
Blue tansy (Tanacetum annuum) and other Asteraceae blue oils.

A common misconception is worth correcting: the blue of cornflower (Centaurea cyanus) petals is not chamazulene but anthocyanin pigment — chamazulene’s blue is specific to the distilled essential oils of the proazulene-bearing Asteraceae above.

Discovery & Synthesis

The blue of chamomile oil was noticed long before it was understood. The chromophore was isolated from chamomile oil and named “azulene” — from the Spanish azul, blue — by the perfumer-chemist Septimus Piesse in 1863, who described it as a blue hydrocarbon; the same blue was soon found in yarrow and wormwood oils. Working out what azulenes actually were took decades more: the fused cyclopentane–cycloheptane azulene skeleton was established by Plattner and Pfau in the 1930s, and chamazulene’s specific structure — 7-ethyl-1,4-dimethylazulene — was resolved in 1953.

Manufacture today is essentially a thermal process, not a synthesis: chamazulene is obtained by steam-distilling proazulene-rich Asteraceae (chamomile, yarrow, Artemisia), which decomposes matricin to the blue hydrocarbon ^{1Reference 1Gabbanini S et al. · 2024Photochemical and oxidative degradation of chamazulene contained in Artemisia, Matricaria and Achillea essential oils and setup of protection strategiesView study →}. Where a stable blue azulene is wanted for cosmetics, industry more often reaches for the related, more robust guaiazulene (a distinct, largely semi-synthetic azulene from guaiac wood or made synthetically) rather than the light-sensitive chamazulene. Total synthesis of chamazulene is chemically possible but not the commercial route.

Patents: not yet researched.

Toxicity & Safety

Chamazulene carries a low toxicity flag. It occurs in chamomile and yarrow essential oils that have a long record of traditional use, it is itself an antioxidant, and no distinctive toxicity is attributed to the isolated molecule. The meaningful cautions belong to the whole preparation and its route, not to chamazulene specifically.

Safety at a Glance

Low / no toxicity

No distinctive toxicity for the isolate. A low-toxicity antioxidant azulene occurring in long-used chamomile and yarrow oils.
Daisy-family (Asteraceae) allergy. Contact allergy and cross-reactivity in people sensitive to the daisy family track the sesquiterpene-lactone fraction and whole plant, not chamazulene as such — but they apply to the blue oils that contain it.
Essential oils are a concentrated exposure. The relevant exposure is diluted, distilled oil on skin or inhaled — not the tea; “natural” does not mean the concentrated oil behaves like the herb.
Unstable to air and light. Oxidised, colour-faded oils are chemically different from fresh blue oil; store cool, dark and well-sealed.

Reproductive note (prose only). No dedicated reproductive-toxicity dataset exists for isolated chamazulene. The pregnancy cautions often attached to wormwood and mugwort belong to thujone and those whole plants, not to chamazulene. Pregnancy and lactation decisions are made on the herb or product page where intake is decided, not on this molecule page; no isolate-specific verdict is issued here.

Dosage

There is no established or recommended human dose for isolated chamazulene. It is not sold or used as a stand-alone drug; human exposure is entirely indirect — as a variable fraction of steam-distilled chamomile, yarrow and related blue essential oils, used diluted on the skin, in cosmetics, or inhaled in aromatherapy. Because chamazulene may make up anywhere from a trace to nearly half of such an oil ^{7Reference 7Németh E · 2008Biological activities of yarrow species (Achillea spp.)View study →}, and degrades on storage ^{1Reference 1Gabbanini S et al. · 2024Photochemical and oxidative degradation of chamazulene contained in Artemisia, Matricaria and Achillea essential oils and setup of protection strategiesView study →}, the delivered amount is inherently imprecise.

The figures cited here — LTB4 inhibition at ~10–15 µM, antioxidant IC50 values of ~2–18 µM ^{2,3Reference 2Safayhi H et al. · 1994Chamazulene: an antioxidant-type inhibitor of leukotriene B4 formationView study →Reference 3Rekka EA et al. · 1996Investigation of the effect of chamazulene on lipid peroxidation and free radical processesView study →} — are in-vitro potencies, not doses, and do not convert to a human intake. These are research values, not a personal recommendation.

References

Gabbanini S, Neba JN, Matera R, Valgimigli L (2024). Photochemical and oxidative degradation of chamazulene contained in Artemisia, Matricaria and Achillea essential oils and setup of protection strategies. Molecules. https://pubmed.ncbi.nlm.nih.gov/38893479/
Safayhi H, Sabieraj J, Sailer ER, Ammon HP (1994). Chamazulene: an antioxidant-type inhibitor of leukotriene B4 formation. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/7997466/
Rekka EA, Kourounakis AP, Kourounakis PN (1996). Investigation of the effect of chamazulene on lipid peroxidation and free radical processes. Research Communications in Molecular Pathology and Pharmacology. https://pubmed.ncbi.nlm.nih.gov/8827832/
Capuzzo A, Occhipinti A, Maffei ME (2014). Antioxidant and radical scavenging activities of chamazulene. Natural Product Research. https://pubmed.ncbi.nlm.nih.gov/24980540/
Querio G, Antoniotti S, Foglietta F, Bertea CM, Canaparo R, Gallo MP, Levi R (2018). Chamazulene attenuates ROS levels in bovine aortic endothelial cells exposed to high glucose concentrations and hydrogen peroxide. Frontiers in Physiology. https://pubmed.ncbi.nlm.nih.gov/29615934/
Ramadan M, Goeters S, Watzer B, Krause E, Lohmann K, Bauer R, Hempel B, Imming P (2006). Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substances. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/16872141/
Németh E, Bernáth J (2008). Biological activities of yarrow species (Achillea spp.). Current Pharmaceutical Design. https://pubmed.ncbi.nlm.nih.gov/19075697/
Benedek B, Rothwangl-Wiltschnigg K, Rozema E, Gjoncaj N, Reznicek G, Jurenitsch J, Kopp B, Glasl S (2008). Yarrow (Achillea millefolium L. s.l.): pharmaceutical quality of commercial samples. Pharmazie. https://pubmed.ncbi.nlm.nih.gov/18271298/
Srivastava JK, Shankar E, Gupta S (2010). Chamomile: a herbal medicine of the past with a bright future. Molecular Medicine Reports. https://pubmed.ncbi.nlm.nih.gov/21132119/